Actively Recruiting

Phase 4
Age: 18Years - 50Years
All Genders
NCT07154719

GLP-1R Actions on Muscle and the Skeleton

Led by Pennington Biomedical Research Center · Updated on 2026-04-16

50

Participants Needed

1

Research Sites

59 weeks

Total Duration

On this page

Sponsors

P

Pennington Biomedical Research Center

Lead Sponsor

N

National Institutes of Health (NIH)

Collaborating Sponsor

AI-Summary

What this Trial Is About

The GRAMS study objectives are to assess the musculoskeletal changes that occur after weight loss using GLP-1 based therapy. A lifestyle intervention with diet and exercise is included to assess any mitigating effects are provided, versus a control group with regular exercise and diet.

CONDITIONS

Official Title

GLP-1R Actions on Muscle and the Skeleton

Who Can Participate

Age: 18Years - 50Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Have a body mass index (BMI) between 30 and 40 kg/m2 (inclusive)
  • Be between 18 and 50 years of age (inclusive)
  • Be a non-Hispanic Black male or female enrolled at PBRC
  • Be a rural male or female enrolled at MaineHealth
  • Female subjects must be premenopausal
  • Female subjects must have had their last menstrual period less than 60 days before screening
  • Female subjects must have no menopausal-associated vasomotor symptoms
  • All subjects must be able to use the Lifestyle Toolkit as prescribed for the intervention group
Not Eligible

You will not qualify if you...

  • Males and females over 50 years of age
  • Menopausal female subjects
  • Use of systemic corticosteroids or other medications known to cause muscle and bone loss
  • Use of medications that affect weight status
  • Contraindications to tirzepatide as per package insert
  • History of malignancy except non-melanoma skin cancer
  • Known osteoporosis or current use of osteoporosis treatments
  • Uncontrolled thyroid or parathyroid disease
  • Clinically significant blood, kidney, liver disease, or diabetes
  • Females of childbearing potential not agreeing to effective contraception during the study
  • Inability to follow the Lifestyle Toolkit as prescribed
  • Clinical depression with a PHQ-9 score of 15 or higher
  • Unable to provide informed consent
  • Under 18 years of age
  • Pregnancy
  • Incarceration
  • Contraindications to MRI (e.g., metallic implants, claustrophobia, weight over 500 pounds)
  • Vitamin D level below 15 ng/ml at baseline
  • Significant EKG abnormalities posing risk for weight management therapies

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Pennington Biomedical Research Center

Baton Rouge, Louisiana, United States, 70808

Actively Recruiting

Loading map...

Research Team

R

Robert L Dubin, MD

CONTACT

S

Seaneen Hebert, MS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here